Skip to content

To evaluate changes in its DNA and RNA makeup in the tumor of any given patient over the course of her metastatic cancer

â??Mapping of Breast Cancer â??Transitionsâ?? to identify the Underlying Biology of Tumour Progression using Next Generation Sequencing (NGS) Technologiesâ??

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/11/007430
Enrollment
10
Registered
2016-11-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Breast Cancer

Interventions

Intervention1: Basic Research: Paired tumor and blood samples from Breast cancer patients will be collected at the time of accrual and at first and subsequent progression.

Sponsors

SCIENCE ENGINEERING RESEARCH BOARD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients just diagnosed with recurrent/metastatic breast cancer after a previous diagnosis and treatment of non-metastatic breast cancer OR de nevo metastatic breast cancer Patients whose primary tumors are stored in the Tumor Tissue Repository of Tata Memorial Hospital in liquid nitrogen Patients willing to provide written informed consent to participate in the study including biopsies from recurrent/metastatic sites and longitudinal follow-up in their metastatic course Patients in whom biopsy from recurrent/metastatic sites can be performed with reasonable safety Patients whose tumors are triple negative by IHC (ER-/PR-/HER2-) Patients willing to receive the usual standard treatment for metastatic breast cancer

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

MeasureTime frame
Compare sequential biopsies obtained at successive transition points to determine the impact of progression of the disease and treatment on tumor heterogeneity To determine whether breast cancer progression is parallel or sequential To determine the role of/ degree of clonal selection during the various transitions through defined clinical stages from primary tumor to end stage disease Identify novel targets and assess their role as drivers in the progression of the disease Timepoint: Patients with Triple negative breast cancer detected with newly developed metastatic breast cancer after a previous diagnosis and treatment of non-metastatic breast cancer (whose primary tumors are archived in the TMH Tumor Tissue Repository) OR de nevo metastatic breast cancer

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Centre

sudeepgupta04@yahoo.com02224177201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026